The Institute and Allumiqs join forces to offer advanced bioanalytical solutions for research
SOURCE: Allumiqs and the Research Institute of McGill University Health Centre (The Institute)
May 6, 2025
The Research Institute of McGill University Health Centre (The Institute) is proud to announce a new partnership with Allumiqs, a trailblazing multiomics Contract Research Organization (CRO). By combining their strengths, the two organizations aim to provide researchers with expanded access to cutting-edge bioanalytical services, helping accelerate discoveries in biopharma, biotech, and academia.
At the heart of the partnership is a shared commitment to advancing science through integrated, cross-platform solutions. Researchers will benefit from a streamlined “one-stop shop” that connects Allumiqs' expertise in multiomics - proteomics, metabolomics, lipidomics - and advanced data analytics with The Institute’s state-of-the-art instrumentation, preclinical services, and specialized expertise housed within the Centre for Translational Biology (CTB) Technology Platforms.
One immediate advantage for researchers: Allumiqs’ customers will now have access to all The Institute’s Technology Platforms, including small animal imaging services through The Institute’s Small Animal Imaging Lab (SAIL) to support studies that link molecular insights with in vivo biological models. Research teams at The Institute will benefit from enhanced multiomics profiling and data integration services developed by Allumiqs, opening new possibilities for biomarker discovery, patient stratification, and mechanism-of-action research.
"Bringing together subject matter experts, services, and technologies in a collaborative ecosystem delivers exponential benefits to research teams,” explains Derek Gooderham, Chief Commercial Officer at Allumiqs. “This partnership with The Institute helps simplify procurement, streamline projects, and most importantly, empowers scientists with faster access to comprehensive solutions.”
The collaboration also supports The Institute’s 2030 Vision of advancing precision health across the life course by enhancing access to next-generation multiomic technologies and fostering partnerships that strengthen the long-term sustainability of its platforms.
“This partnership expands our service offering, fosters new scientific collaborations, and accelerates discovery and innovation across sectors,” said Patrice Vaillancourt, Manager, Operations and Platforms at The Institute. “By joining forces with Allumiqs, we are better positioned to deliver cross-platform, integrated capabilities that help researchers turn complex data into meaningful insights.”
About Allumiqs
Allumiqs is a multiomics Contract Research Organization (CRO) specializing in proteomics, metabolomics, lipidomics, and small molecule analysis powered by advanced mass spectrometry. Delivering precise, high-impact data, Allumiqs helps biotech and biopharma organizations de-risk drug development and accelerate innovations from discovery to patient value. As one of the first CROs to develop Data Independent Acquisition (DIA) mass spectrometry methods and applications, Allumiqs set the standard for comprehensive quantification in untargeted workflows across proteins, metabolites, and lipids. Allumiqs is the expert in integrating diverse data sources—like proteomics and metabolomics with external datasets such as genomics—to identify and highlight critical features that differentiate conditions, enabling breakthrough insights in biomarker discovery, patient stratification, and mechanism of action (MOA) research. Collaborating with Allumiqs brings customers access to its dedicated team of scientists and world-class channel partners. allumiqs.com